

INITIATION OF COVERAGE
Dave Storms, CFA
Dave@stonegateinc.com

214-987-4121

Market Statistics in USD

Price	\$ 2.24
52 week Range	\$1.12 - \$7.00
Daily Vol (3-mo. average)	627,463
Market Cap (M)	\$ 70.2
Enterprise Value (M)	\$ 69.2
Shares Outstanding: (M)	31.9
Float (M)	23.4

Financial Summary in USD

Cash (M)	\$ 2.8
Cash/Share	\$ 0.09
Debt (M)	\$ -
Equity (M)	\$ 6.8
Equity/Share	\$ 0.17


COMPANY DESCRIPTION

OS Therapies is a clinical-stage oncology company developing OST-HER2, an immunotherapy for osteosarcoma and other solid tumors. OST-HER2 harnesses Listeria bacteria to trigger an immune response against the HER2 protein and has received Rare Pediatric Disease, Fast-Track, and Orphan Drug designations from the FDA and EMA. A Phase 2b trial in recurrent lung metastatic osteosarcoma showed a statistically significant benefit in 12-month event-free survival. The Company plans to submit a BLA in 2025 and, if approved, could receive a Priority Review Voucher. OST-HER2 has also demonstrated activity in breast cancer and holds conditional USDA approval for canine osteosarcoma.

OS THERAPIES INC. (NYSE: OSTX)
Company Updates

OS Therapies advanced meaningful clinical, regulatory, and financial milestones in 2Q25 as it moves closer to bringing OST-HER2 to patients with recurrent, fully resected, pulmonary metastatic osteosarcoma. Importantly, the FDA confirmed that OST-HER2 meets the biological definition of a Regenerative Medicine Advanced Therapy (RMAT) and issued a Biologics License Application (BLA) number in preparation for an Accelerated Approval submission. Final 12-month Event Free Survival (EFS) results from the Phase 2b trial demonstrated statistically significant improvement, supported by interim 2-year Overall Survival (OS) data, further validating the clinical benefit. With a U.S. commercial partnership secured with Eversana, OS Therapies is positioning for a potential U.S. launch in the first half of 2026.

Pipeline Overview: OST-HER2 remains the Company's lead program. The therapy, built on a listeria-based immunotherapy platform, has demonstrated compelling efficacy in osteosarcoma, an area with no new FDA-approved therapies in over 40 years. Beyond osteosarcoma, OS Therapies expanded its portfolio by acquiring Ayala's listeria immunotherapy platform, which adds four additional clinical-stage and eight pre-clinical-stage programs. The Company also formed OS Animal Health, a subsidiary to explore applications of OST-HER2 in canine osteosarcoma, supported by positive veterinary trial data.

Regulatory Advancements: In August 2025, OS Therapies held a productive End of Phase 2 Meeting with the FDA, aligning on CMC and non-clinical matters, and confirming no safety concerns with OST-HER2. The Company remains on track to begin rolling BLA submissions in September 2025. Internationally, OS Therapies has submitted an ILAP to the UK MHRA and scheduled an EMA rapporteur meeting in October 2025, with the agencies signaling an intent to synchronize reviews via Project Orbis. If approved before September 30, 2026, OST-HER2's rare pediatric disease designation could qualify the Company for a Priority Review Voucher (PRV), potentially monetizable at ~\$155–160M based on recent transactions.

Financial Performance: For 2Q25, OS Therapies reported a net loss of \$4.5M, compared to \$1.6M in 2Q24, reflecting increased R&D and G&A expenses related to clinical and regulatory progress. Cash stood at \$2.8M at quarter-end, with recent financing extending runway into 2027. Specifically, the Company raised \$4.2M in July 2025 through a warrant exchange and inducement, completed an additional \$3.7M warrant exchange in September 2025, and subsequently terminated its equity line of credit, citing reduced burn rate and sufficient liquidity. Management expects this strengthened balance sheet, combined with the potential monetization of a PRV, to provide a multi-year capital runway to support commercialization.

Valuation: We use a probability-adjusted Discounted Cash Flow Model when valuing OSTX. Our valuation model returns a valuation range of \$7.09 to \$9.94 with a midpoint of \$8.29 based on a discount rate range of 12.50% to 17.50%. We note that this model is highly levered to the out years due to the long term nature of OSTX's industry, leading to the potential for dramatic re-ratings as new information becomes available.

Business Overview


OS Therapies Inc. (NYSE: OSTX) is a clinical-stage biotechnology company dedicated to developing novel oncology therapies for rare and underserved cancers. Established in 2019 and headquartered in Maryland, the Company was founded with the mission to bring forward innovative immunotherapies where few treatment options exist. Its lead program, built on a *Listeria monocytogenes* immunotherapy platform, is advancing toward regulatory submission in osteosarcoma, a rare pediatric bone cancer that has seen no new drug approvals in over four decades. By combining scientific innovation, strong leadership, and a disciplined development strategy, OS Therapies is positioning itself as a potential first mover in rare oncology.

Management has played a central role in shaping the Company's strategy and progress to date. The organization is led by Paul Romness, MHP, Chairman & Chief Executive Officer, who brings decades of experience in healthcare policy, business development, and corporate strategy. Supporting him is Chris Acevedo, Chief Financial Officer, who has guided the Company's financial operations, capital structure, and efficiency improvements. The leadership team also includes Gerald Commissioning, Chief Business Officer, whose expertise in clinical operations and regulatory execution strengthens the Company's ability to advance programs through pivotal milestones. Together, this management team brings 100+ years of combined experience, with ~20 drug launches and ~10 licensing deals completed.

OS Therapies' strategy extends beyond a single therapy. While the Company's immediate focus is advancing its lead immunotherapy candidate through the regulatory process in the U.S. and Europe, management has taken deliberate steps to build a broader pipeline and diversify the platform's applications. This includes leveraging its proprietary antibody-drug conjugate (ADC) technology, which incorporates a novel linker-payload system designed to enhance efficacy and safety across solid tumor indications. The Company has also structured its operations to capture opportunities in both human and animal health, reflecting a long-term vision that balances near-term regulatory milestones with a diversified oncology portfolio.

In recent quarters, OS Therapies has demonstrated its ability to execute this strategy. The Company reported statistically significant results in a late-stage clinical trial in osteosarcoma, completed the consolidation of key intellectual property surrounding its *Listeria*-based platform, and extended its exclusivity runway with new patent issuances. At the same time, it has reduced its burn rate following trial completion, strengthened its balance sheet through financing, and extended its operational runway. These developments underscore management's ability to advance critical programs while maintaining financial discipline—an essential quality for a company operating in rare oncology.

Exhibit 1: Market Overview



Source: Company Reports

Exhibit 2: Investment Highlights



Source: Company Reports


Looking ahead, OS Therapies is well positioned with multiple regulatory interactions scheduled in 2025, including FDA and European agency meetings that are expected to guide the path to market for its lead therapy. If successful, the Company could deliver the first meaningful therapeutic advance in osteosarcoma in over 40 years, with potential applicability in other HER2-expressing cancers. Backed by a leadership team with demonstrated expertise, a diversified strategic plan, and strong alignment with patient advocacy groups, OS Therapies represents an emerging player in oncology drug development, balancing near-term value creation opportunities with a platform capable of driving long-term growth.

Pipeline Overview - Clinical-stage Pipeline (Listeria platform)

Osteosarcoma (OS) / OST-HER2: OST-HER2 is the Company’s lead program and represents its most advanced clinical initiative. The therapy is designed to stimulate the immune system using a Listeria monocytogenes-based platform to target HER2-expressing tumors. Osteosarcoma is a rare pediatric bone cancer with approximately 1,000 new U.S. cases annually and 20,000 globally, with no new therapies approved in over 40 years. OS Therapies reported positive Phase 2b data in recurrent, fully resected, lung metastatic osteosarcoma, showing a statistically significant improvement in 12-month event-free survival. The Company plans to submit a Biologics License Application (BLA) in 2025, with the potential to receive Accelerated Approval from the FDA. If approved, OST-HER2 could become the first new treatment for osteosarcoma in decades and would qualify OS Therapies for a Priority Review Voucher (PRV), which carries significant standalone value (estimated ~\$150 million).

Exhibit 3: Clinical Stage Pipeline

Clinical-stage Pipeline (Listeria platform)



Trial	Preclinical	Phase 1	Phase 2a	Phase 2b	Phase 3	Approval	Launched
Osteosarcoma (OS) (OST-HER2)	Positive Phase 2b Data. Targeting Accelerated Approval Q4/25				<ul style="list-style-type: none"> Orphan drug designation Fast Track Designation Rare Pediatric Disease Designation 		
HPV Cancers (OS) (OST-AXLA)	Completed Phase 3a Data: Pending data release and Phase 3b trial						
Non-Small Cell Lung Cancer* (NSCLC) (OST-503)	Metastatic disease alone & in combi w/Keytruda						
Non-Small Cell Lung Cancer* (NSCLC) (OST-503)	Frontline alone & in combo w/Keytruda						
Glioblastoma (GBM) (OST-503)	Glioblastoma alone & in combo Keytruda						
Breast Cancer (BC) (OST-HER2)	HER2+ BC in Combination w/HER2 Abs						
Prostate Cancer* (PC) (OST-PSA)	Biochemically Recurrent Disease						
Canine OS (OST-HER2)	USDA conditional approval achieved. Full approval path pending updated regulatory guidance						

Source: Company Reports

HPV Cancers (OS) / OST-AXLA: OST-AXLA is being developed to target HPV-related cancers, leveraging the same *Listeria*-based immunotherapy platform. The program has already produced positive Phase 3a clinical data, with further confirmatory trials (Phase 3b) in planning. HPV-driven cancers remain a high-burden global disease, impacting cervical, head and neck, and other tumor types. OST-AXLA provides OS Therapies with an opportunity to extend its technology beyond pediatric bone cancer and into more prevalent indications with broader market potential. The HPV cancer market is well established, with multiple therapeutic entry points, making OST-AXLA a potential mid-term value driver if ongoing development is successful.

Non-Small Cell Lung Cancer (NSCLC) / OST-503: OST-503 is advancing through early clinical development in non-small cell lung cancer (NSCLC), both as a monotherapy and in combination with Merck’s Keytruda. NSCLC is the most common form of lung cancer, accounting for approximately 85% of cases worldwide, representing a multi-billion-dollar market opportunity. OST-503 is being tested in metastatic disease settings

and also in frontline combinations. By targeting immune pathways and leveraging synergy with checkpoint inhibitors, OS Therapies seeks to position OST-503 as a differentiated option in a competitive oncology space. While early in development, this program has the potential to expand the Company's footprint significantly in one of the largest oncology markets.

Glioblastoma (GBM) / OST-503: In addition to NSCLC, OST-503 is also being explored in glioblastoma multiforme (GBM), a highly aggressive brain cancer with poor survival rates and limited treatment options. The program is being developed as both a monotherapy and in combination with checkpoint inhibitors such as Keytruda. Given GBM's notoriously high unmet need and the failure of most therapeutic approaches to meaningfully extend survival, OST-503 represents a high-risk but potentially high-reward asset. If clinical data demonstrates immune activity within the central nervous system, this program could open new strategic opportunities for OS Therapies in neuro-oncology.

Breast Cancer (BC) / OST-HER2: Originally developed for breast cancer, OST-HER2 has already shown encouraging preclinical and Phase 1 data in HER2-positive breast cancer, demonstrating tumor regression in both spontaneous and metastatic models. A Phase 1 trial in advanced HER2+ solid tumors established a recommended therapeutic dose and showed early signs of efficacy, including cases of clinical improvement in heavily pre-treated patients. With a breast cancer market exceeding \$35 billion annually, reinitiating development in this indication post-osteosarcoma approval could represent a substantial expansion opportunity. Management has indicated that once OST-HER2 is on the market in osteosarcoma, renewed interest in breast cancer trials will follow.

Prostate Cancer (PC) / OST-PSA: OST-PSA is a therapeutic candidate designed for patients with biochemically recurrent prostate cancer, a stage of the disease where PSA levels rise following initial therapy but before clinical progression. This is a challenging disease state with few treatment options and represents an attractive entry point for novel immunotherapies. OST-PSA remains in early clinical development, with proof-of-concept studies planned. If efficacy is demonstrated, the program could establish a foothold in prostate cancer, one of the most prevalent cancers in men globally.

Canine OS / OST-HER2: OST-HER2 is also being developed for canine osteosarcoma through the Company's veterinary subsidiary, OS Animal Health. Conditional approval has already been granted by the USDA, and a full approval pathway is under way with confirmatory trials in partnership with the University of Pennsylvania's veterinary school. Canine osteosarcoma represents an attractive \$150 million+ market opportunity, with significant overlap in biology to human osteosarcoma. Success in this program not only provides near-term commercial revenue potential but also strengthens translational credibility for OST-HER2 in human oncology.


Pipeline Overview - Preclinical Pipeline (Listeria & ADC Platform)

Ovarian Cancer / OST-tADC: OS Therapies is developing OST-tADC for ovarian cancer, part of its tunable Antibody-Drug Conjugate (tADC) platform. This proprietary approach leverages a patented silicone linker and Conditionally Active Payload (CAP) technology to deliver cytotoxic payloads more precisely, improving both safety and efficacy. Ovarian cancer remains an area of high unmet need with frequent recurrence following chemotherapy. Preclinical work suggests OST-tADC has potential to overcome limitations of existing ADCs and may move toward clinical evaluation in the coming years.

Breast Cancer / OST-tADC: Beyond HER2 immunotherapy, OS Therapies is also targeting breast cancer through its tADC platform. This program remains in preclinical testing but represents a potential avenue to compete in one of the largest oncology markets by offering differentiated ADC technology. The ability to tune drug conjugates for specific tumor biology could make OST-tADC attractive as either a standalone program or in partnership with larger oncology companies seeking next-generation ADC platforms.

Other Solider Tumors / OST- tADC: The tunable ADC platform is not limited to ovarian or breast cancer. OS Therapies is exploring multiple solid tumor applications, with early-stage research indicating broad applicability. ADCs have emerged as a leading class in oncology therapeutics, and OS Therapies’ proprietary CAP-enabled linker system could offer best-in-class safety and efficacy attributes. Preclinical development continues across several undisclosed tumor types, providing optionality for future clinical expansion.

Exhibit 4: Preclinical Pipeline



Source: Company Reports

Solid Tumors / 8 undisclosed OST-Lm therapeutic candidates: In addition to named programs, the Company is advancing a pipeline of eight undisclosed candidates based on its *Listeria*-monocytogenes (OST-Lm) platform. These preclinical assets are focused on a range of solid tumors and represent the depth and versatility of the Company’s platform. While details remain confidential, the breadth of activity highlights management’s intent to scale the *Listeria* platform beyond its initial indications, creating a diversified pipeline with multiple “shots on goal”.

Growth Drivers

First-mover in osteosarcoma with a near-term regulatory path: OS Therapies is positioned to deliver the first new drug therapy for osteosarcoma in more than four decades, addressing rare pediatric cancer with high post-recurrence mortality and no approved adjuvant options to prevent relapse. Positive Phase 2b data in recurrent, fully resected, lung-metastatic osteosarcoma underpin a plan to seek U.S. Accelerated Approval, with a rolling BLA targeted for 2025. The company is building a matched external-control dataset (OST-400) to align with FDA guidance on statistical methodology for single-arm data packages in rare diseases. If approved, OST-HER2 could also yield a monetizable Priority Review Voucher (PRV).

Emerging prostate cancer program as the next growth driver: In parallel, OS Therapies is advancing its prostate cancer program, which is expected to generate additional clinical data shortly. Management views this program as the company’s #2 development priority, positioned directly behind osteosarcoma while OST-HER2 progresses through FDA review. With prostate cancer representing a significantly larger commercial opportunity, this program highlights OS Therapies’ ability to expand beyond rare pediatric cancers into broader oncology indications, strengthening the company’s medium-term growth outlook.

Platform leverage across HER2+ and immuno-oncology: Beyond osteosarcoma, the *Listeria*-based immunotherapy platform (OST-HER2) has clinical and preclinical signals across HER2-expressing tumors, including breast cancer, creating optionality to expand into larger markets after an initial rare-disease foothold. Programs such as OST-503 (NSCLC/GBM, alone and in combination with checkpoint inhibitors) and OST-AXLA (HPV-associated cancers) extend the immuno-oncology footprint. This “lead-indication first, platform follow-through” approach can compound clinical learning and reduce per-program execution risk.

Second growth pillar: next-generation, tunable ADCs: OS Therapies’ proprietary tADC platform couples a patented silicone linker with conditionally active payload technology designed to improve therapeutic index and enable multiple payloads per linker. The company organized OS Drug Conjugates (OSDC) to pursue partnering and indication expansion in ovarian, breast, and other solid tumors—creating a separate deal vector alongside immunotherapy. New U.S. IP covering commercial manufacturing extends platform exclusivity to ~2040, supporting durable returns on partnered and wholly owned programs.

Exhibit 4: OST-HER2 Platform Drivers

Catalyst Rich Advanced OST-HER2 Cancer Therapeutic Platform



Multiple Near-Term Clinical Milestones

- Phase 2b trial for OST-HER2 in Osteosarcoma positive data: Announced Jan 2025
- Path to Pivotal OST-HER2 Canine OS study to support full approval pending USDA alignment: 1H/25
- Key FDA Meeting: Q2/25
- BLA Submission: Q3/25
- Accelerated Approval: Q4/25

NYSE American: OSTX



Significant Market Opportunity

- TAM Human Osteosarcoma – \$1.2B
- Market Opportunity for OST-HER2 in Osteosarcoma: \$500M
- TAM Canine Osteosarcoma – \$150M+
- tADC platform – \$311 billion



Favorable Regulatory Review Process

- Osteosarcoma (Human and Animal): No new approvals in 40+ years
- Orphan, Fast Track, Rare Pediatric Disease Designations granted by the FDA and EMA for OST-HER2
- Priority Review Voucher – if OST-HER2 approved, PRV value = \$150M



Experienced, Successful Leadership

- Proven management team with large & early-stage pharma experience with multiple successful product launches
- Expert OS scientific advisory board
- Strong patient advocacy & commercialization advisors
- Cash on hand into mid-2026

Osteosarcoma (“Bone Cancer”) is a solid tumor of the bone

- 1,000 cases/year in US; 20,000 globally
- Most Cases Present In Patients 15-20 Years Of Age
- No New Treatments In Over 40 Years
- METS (Lung) In ~40-50%+ Of Patients: **400 to 500 patients**
- High Lung METS Recurrence: Fatality Rate: ~ 90%
- Time To Mortality Upon METS Recurrence: ~12 Months
- Only Treatment for Recurrent METS: Lung METS Surgery
 - No drug therapy used (chemotherapy failed)
- Objective = Prevent Recurrence - Increase Overall Survival

Standard of Care (SOC):

- Primary OS – a) Amputation of leg, extremity b) orthopedic implant and highly toxic 9-month chemotherapy regimen with 10% treatment-associated mortality
- Secondary OS / Recurrent Disease: None

32 NYSE American: OSTX

Source: Company Reports

Dual human–animal health strategy to add near-term revenue potential: OST-HER2 holds conditional USDA approval for canine osteosarcoma; OS Animal Health will pursue full approval via a confirmatory study at the University of Pennsylvania and expand into preventive/therapeutic settings. The veterinary franchise targets a six-figure incident population annually in dogs and a company-estimated \$150M+ market, offering earlier revenue line-of-sight than typical human oncology timelines while reinforcing translational credibility for the human program.

Ecosystem alignment—regulators, advocates, and partners: The Company has advanced multi-agency dialogues (FDA Type D, End-of-Phase-2; UK MHRA Scientific Advice; EMA pathway planning) and has been featured in the osteosarcoma community (MIB Factor keynote), supported by leading advocacy groups. Operationally, OS Therapies partnered with J&J Innovation (JLABS) for lab/office resources—useful for capital-efficient scale-up. These relationships can accelerate review cycles, trial enrollment, and real-world adoption at launch.

Financial catalysts and capital efficiency: Management reports a markedly lower burn after completing Phase 2b dosing and initiating regulatory workstreams, with cash of ~\$3.0M at March 31, 2025 and an operating plan targeted to extend into mid-2026 (subject to financing). A potential PRV from a successful pediatric approval creates a non-dilutive capital lever, historically saleable in the \$100M–\$300M range depending on market conditions (company cites ~\$150M in its materials).

Market Overview


Osteosarcoma: small incidence, high unmet need, concentrated decision-makers.

In the U.S., bone and joint cancers occur at roughly 1.0 per 100,000 annually, with osteosarcoma the most common primary bone sarcoma and incidence peaking in adolescence; global osteosarcoma cases are commonly cited around ~20,000 per year with ~1,000 in the United States. Standard of care involves resection and intensive chemotherapy, yet outcomes after lung metastasis remain poor and 5-year survival has plateaued for decades. This creates a rare-disease market in which a first-in-class adjuvant-type therapy that demonstrably reduces recurrence could see rapid uptake among a concentrated network of pediatric oncology centers (e.g., COG institutions).

Clinical endpoints and regulatory incentives shape adoption.

Event-Free Survival (EFS)—the primary endpoint in OS Therapies' Phase 2b—captures time to recurrence, treatment discontinuation, or death, making it fit-for-purpose in settings where preventing relapse is the clinical goal. In pediatric rare diseases, the FDA's Rare Pediatric Disease program offers PRVs upon approval; these vouchers are transferrable and have traded at sizable prices, creating a financing bridge for launch and post-marketing commitments.

Exhibit 4: Bone and Joint Cancer Statistics



Source: National Cancer Institute


HER2-positive malignancies: large follow-on addressable pools.

Approximately 20%–30% of breast cancers overexpress HER2, a well-validated target with multiple approved antibodies and ADCs. While HER2-directed standards are established, an approved Listeria-based immunotherapy could open combination or maintenance strategies in select HER2+ settings after the initial osteosarcoma foothold—particularly where T-cell priming and epitope spreading may complement antibody or ADC mechanisms.

Immuno-oncology and ADC context: rising modalities with room for differentiation.

Checkpoint inhibitors transformed several adult solid tumors, yet pediatric sarcomas remain underserved—supporting regulatory openness to novel immunotherapies with persuasive clinical evidence. In parallel, Antibody-Drug Conjugates (ADCs) have become a leading modality; a 2025 review notes ~15 ADCs approved globally by 2024, with robust pipelines and sustained pharma business-development interest. OS Therapies' tADC approach (silicone linker + conditionally active payloads) is designed to push the efficacy–safety frontier, a key adoption driver as payers and clinicians scrutinize tolerability and durability across crowded tumor segments.

Exhibit 4: ADCs: Current and Future Biopharmaceuticals



Source: Journal of Hematology & Oncology

Veterinary oncology: translational proof and incremental revenue.

Canine osteosarcoma is common and biologically relevant to the human disease. Published veterinary trials of Listeria-HER2 constructs (UPenn) have shown immune responses and promising survival extensions, and OS Therapies has already achieved conditional USDA approval in dogs. A dedicated animal-health pathway offers earlier commercialization potential and real-world evidence that can inform human oncology strategy—while addressing a market the company estimates at \$150M+.

Total addressable markets and launch dynamics.

Company materials frame large adjacencies: cancer immunotherapy (> \$100B class), breast cancer (>\$30B), and human osteosarcoma (~\$1.2B), with a U.S. topline opportunity suggested at \$500M+ for OST-HER2 in osteosarcoma if broadly adopted—figures that reflect the mix of small patient numbers, high severity, concentrated prescriber bases, and premium orphan pricing. While these are company estimates rather than external forecasts, they outline the strategic logic: win a scarce, high-need pediatric indication first, then leverage the platform into larger HER2+ and ADC-amenable markets.

Bottom line.

The market thesis rests on three intersecting trends: (1) a high-unmet-need, guideline-driven pediatric niche where a recurrence-preventing therapy can become standard quickly; (2) modalities with momentum (IO, ADC) where OS Therapies' platforms can differentiate and partner; and (3) policy incentives (PRVs, orphan/fast-track frameworks) that can accelerate access and defray capital needs. Together, these vectors support a credible launch arc in osteosarcoma with meaningful expansion pathways across HER2+ and ADC-addressable solid tumors.

Risks

As with any investment, there are certain risks associated with OS Therapies' operations as well as with the surrounding economic and regulatory environments common to the pharmaceutical industry.

- The Company has no history of net income, dividends, or cash flow and there can be no assurance that the Company will be profitable going forward. In the case that the Company cannot create enough revenue to sustain on-going business activities, the Company's most likely source of financing will be through the sale of existing securities or high-cost borrowing.
- Currently the Company has enough funds to sustain it through the foreseeable future and does not pose a going concern risk. We do however recognize that at some point the Company may need to raise more funds to sustain its operations until it begins revenue generation. Should the Company be unable to raise the necessary funds this would create a going concern risk.
- The Company is subject to regulatory risk as pharmaceutical activities are subject to laws and regulations imposed by local and state government authorities. Any future changes in the laws, regulations, agreements, or judicial rulings could impact or stop the Company from generating a profit on portions or all of its asset portfolio.
- The Company has several patents for intellectual property that the Company has developed. The Company is constantly on guard and ready to defend its intellectual property using litigation if necessary. Should judgements go against the Company this could materially weaken its edge among peers. Additionally, having to pursue litigation as mediation for any infringement could be costly for the Company, regardless of the outcome.
- Should the Company bring any or all its assets to market, there is no guarantee that a profitable market will exist for those treatments. While we have sufficient reason to believe that a market will exist for the Company's assets, this is a fast-moving industry so no guarantees can be made.

VALUATION SUMMARY

We use a probability-adjusted Discounted Cash Flow Model when valuing OSTX. Our valuation model returns a valuation range of \$7.09 to \$9.94 with a midpoint of \$8.29 based on a discount rate range of 12.5% to 17.5% with a midpoint of 15.0%. Key assumptions in this valuation include a current Cancer Immunotherapy market size of approximately 126.0B, a total market size CAGR of 2.4% over the foreseeable future, and a steadily increasing market capture percentage. We also apply a low discount rate to the PRV Sale which we expect to total \$150.0M and be recognized in FY26. Uncertainties that would have a significant impact on this model would be variances in the time to market for any of the leading drug candidates which would impact the risk rating, the capital needs of OSTX going forward which would impact the shares outstanding, and any changes to market capture due to a number of variables that would influence the Company's revenue potential. We note that this model is highly levered to the out years due to the long term nature of OSTX's industry, leading to the potential for dramatic re-ratings as new information becomes available. Currently we believe the Company will begin revenue generation as early as FY26, with operating profitability beginning in FY30 following an annual expense increase of ~2.5%.

BALANCE SHEET

OS Therapies Incorporated												
Consolidated Balance Sheets (\$M)												
Fiscal Year End: December												
	Q1	Q2	Q3	Q4		Q1	Q2	Q3	Q4		Q1	Q2
ASSETS	Mar-23	Jun-23	Sep-23	Dec-23	FY 2023	Mar-24	Jun-24	Sep-24	Dec-24	FY 2024	Mar-25	Jun-25
Cash	0.0	0.0	0.0	0.0	0.0	0.1	0.1	1.9	5.5	5.5	3.0	2.8
Related Party Advance	-	-	-	-	-	-	-	-	-	-	0.0	-
Deferred Offering Cost	0.8	0.8	0.8	0.8	0.8	0.9	1.2	-	-	-	-	-
Prepaid Expenses	-	-	-	-	-	-	-	0.0	-	-	1.1	0.8
Employee Advances	-	-	-	-	-	-	0.1	0.1	-	-	-	-
Total Current Assets	0.8	0.8	0.8	0.8	0.8	1.0	1.3	2.0	5.5	5.5	4.1	3.6
Fixed Asset (Net)	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Other assets	-	-	-	-	-	-	-	-	-	-	0.2	6.8
Total Assets	0.8	0.8	0.8	0.8	0.8	1.0	1.3	2.0	5.5	5.5	4.2	10.3
LIABILITIES AND SHAREHOLDERS' EQUITY												
Accounts Payable	2.7	2.7	2.7	2.7	2.7	2.8	2.9	1.8	1.7	1.7	1.6	2.7
Accrued Interest on Convertible Notes	2.0	2.0	2.0	2.0	2.0	2.3	2.5	-	-	-	-	-
Accrued Expenses	0.2	0.2	0.2	0.2	0.2	0.2	0.2	0.3	0.5	0.5	0.4	0.4
Accrued Payroll and Payroll Taxes	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.0	0.1	0.1	0.0	-
Redemption Premium	4.6	4.6	4.6	4.6	4.6	5.1	5.3	-	-	-	-	-
Short-Term Loan	-	-	-	-	-	0.1	0.3	-	-	-	-	-
Preferred Dividends Payable	0.3	0.3	0.3	0.3	0.3	0.4	0.4	0.4	0.4	0.4	0.4	0.4
Convertible Notes – A (Net Debt Discount)	1.1	1.1	1.1	1.1	1.1	1.1	1.1	-	-	-	-	-
Convertible Notes – A (Related Party Net Debt Discount)	0.1	0.1	0.1	0.1	0.1	0.1	0.1	-	-	-	-	-
Convertible Notes – B (Net Debt Discount)	5.2	5.2	5.2	5.2	5.2	5.2	5.2	-	-	-	-	-
Convertible Notes – C (Net Debt Discount)	3.9	3.9	3.9	3.9	3.9	3.9	3.9	-	-	-	-	-
Convertible Notes – D (Net Debt Discount)	2.0	2.0	2.0	2.0	2.0	2.0	2.0	-	-	-	-	-
Convertible Notes – E (Net Debt Discount)	1.1	1.1	1.1	1.1	1.1	1.1	1.1	-	-	-	-	-
Convertible Notes – F (Net Debt Discount)	1.4	1.4	1.4	1.4	1.4	2.1	3.1	-	-	-	-	-
Warrant Liability (Net of Discount)	-	-	-	-	-	-	-	-	2.0	2.0	1.2	-
Make-whole Stock Liability	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1	-	-	-	-
Total Current Liabilities	24.7	24.7	24.7	24.7	24.7	26.5	28.3	2.6	4.6	4.6	3.5	3.5
TEDCO Grant	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1
Total Liabilities	24.8	24.8	24.8	24.8	24.8	26.6	28.4	2.7	4.7	4.7	3.6	3.6
MEZZANINE EQUITY												
Total Mezzanine Equity	-	-	-	-	-	-	-	-	6.1	-	4.8	1.8
Common Stock	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Preferred Stock	0.0	0.0	0.0	0.0	0.0	-	-	-	-	-	-	-
Additional paid-in capital	5.5	5.5	5.5	5.5	5.5	5.5	5.5	34.7	35.1	35.1	38.1	51.8
Accumulated deficit	(29.5)	(29.5)	(29.5)	(29.5)	(29.5)	(31.0)	(32.6)	(35.4)	(40.4)	(40.4)	(42.3)	(46.9)
Total Parent Net Equity	(24.0)	(24.0)	(24.0)	(24.0)	(24.0)	(25.5)	(27.1)	(0.7)	(5.2)	(5.2)	(4.2)	4.9
TOTAL LIABILITIES, MEZZANINE EQUITY AND STOCKHOLDERS' DEFICIT	0.8	0.8	0.8	0.8	0.8	1.0	1.3	2.0	5.5	(0.5)	4.2	10.3

Source: Company Reports, Stonegate Capital Partners

INCOME STATEMENT

OS Therapies Incorporated																	
Consolidated Statements of Income (in US\$ M, except per share amounts)																	
Fiscal Year End: December																	
	FY 2023	Q1 Mar-24	Q2 Jun-24	Q3 Sep-24	Q4 Dec-24	FY 2024	Q1 Mar-25	Q2 Jun-25	Q3 E Sep-25	Q4 E Dec-25	FY 2025E	Q1 E Mar-26	Q2 E Jun-26	Q3 E Sep-26	Q4 E Dec-26	FY 2026E	
Revenue	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	
Total Revenues	-	-	-	-	-	-	-	-	-	-	-	-	-	-	3.0	14.0	17.0
Administration expenses	1.1	0.3	0.4	1.2	2.1	4.0	3.7	2.3	2.5	2.5	11.0	2.5	2.5	2.5	2.5	10.0	
Other Expenses	3.2	0.4	0.4	1.2	0.9	2.8	1.3	2.5	2.0	2.0	7.8	2.0	2.0	2.0	2.0	8.0	
Total Operating Expenses	4.3	0.6	0.8	2.4	3.0	6.8	5.0	4.8	4.5	4.5	18.8	4.5	4.5	4.5	4.5	18.0	
Operating Income	(4.3)	(0.6)	(0.8)	(2.4)	(3.0)	(6.8)	(5.0)	(4.8)	(4.5)	(4.5)	(18.8)	(4.5)	(4.5)	(3.6)	(0.3)	(12.9)	
Interest & Investment income	0.0	-	-	-	-	-	0.0	0.0	-	-	0.0	-	-	-	-	-	
Interest expense	(3.4)	(0.8)	(0.8)	(0.4)	(0.0)	(2.1)	-	-	-	-	-	-	-	-	-	-	
Other gains/loses	-	-	-	-	(0.0)	(0.0)	1.1	0.3	-	-	1.4	-	-	-	-	-	
Profit Before Taxes	(7.8)	(1.5)	(1.6)	(2.9)	(3.0)	(8.9)	(3.9)	(4.5)	(4.5)	(4.5)	(17.4)	(4.5)	(4.5)	(3.6)	(0.3)	(12.9)	
Provision for Income Tax	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
Net Income	(7.8)	(1.5)	(1.6)	(2.9)	(3.0)	(8.9)	(3.9)	(4.5)	(4.5)	(4.5)	(17.4)	(4.5)	(4.5)	(3.6)	(0.3)	(12.9)	
Cumulative Series A Dividend	(0.1)	(0.0)	-	-	-	(0.0)	-	-	-	-	-	-	-	-	-	-	
Deemed Dividend Series A Convertible P	-	-	-	-	(2.0)	(2.0)	-	-	-	-	-	-	-	-	-	-	
Net Income To Common Stkhdrs	(7.9)	(1.5)	(1.6)	(2.9)	(5.0)	(10.9)	(3.9)	(4.5)	(4.5)	(4.5)	(17.4)	(4.5)	(4.5)	(3.6)	(0.3)	(12.9)	
Basic EPS	\$ (1.46)	\$ (0.13)	\$ (0.26)	\$ (0.18)	\$ (0.31)	\$ (0.88)	\$ (0.18)	\$ (0.19)	\$ (0.18)	\$ (0.18)	\$ (0.69)	\$ (0.18)	\$ (0.18)	\$ (0.14)	\$ (0.01)	\$ (0.51)	
Diluted EPS	\$ (1.46)	\$ (0.13)	\$ (0.26)	\$ (0.18)	\$ (0.31)	\$ (0.88)	\$ (0.18)	\$ (0.19)	\$ (0.18)	\$ (0.18)	\$ (0.69)	\$ (0.18)	\$ (0.18)	\$ (0.14)	\$ (0.01)	\$ (0.51)	
WTD Shares Out - Basic	5.4	11.4	6.0	15.9	16.2	12.4	21.2	25.1	25.4	25.4	25.4	25.4	25.4	25.4	25.4	25.4	
WTD Shares Out - Diluted	5.4	11.4	6.0	15.9	16.2	12.4	21.2	25.1	25.4	25.4	25.4	25.4	25.4	25.4	25.4	25.4	
Growth Rate Y/Y																	
Total cost of revenues	N/M	-39.9%	-48.5%	291.7%	156.4%	56.9%	693.2%	520.5%	84.6%	51.7%	176.5%	-10.0%	-7.0%	0.0%	0.0%	-4.4%	
Net Income	N/M	-21.0%	-37.8%	45.6%	104.2%	14.0%	165.7%	191.3%	56.5%	50.4%	96.0%	16.1%	-0.8%	-20.0%	-93.3%	-25.9%	

Source: Company Reports, Stonegate Capital Partners estimates

IMPORTANT DISCLOSURES AND DISCLAIMER

- (a) The research analyst and/or a member of the analyst's household do not have a financial interest in the debt or equity securities of the subject company.
- (b) The research analyst responsible for the preparation of this report has not received compensation that is based upon Stonegate's investment banking revenues.
- (c) Stonegate or any affiliate have not managed or co-managed a public offering of securities for the subject company in the last twelve months, received investment banking compensation from the subject company in the last 12 months, nor expects or receive or intends or seek compensation for investment banking services from the subject company in the next three months.
- (d) Stonegate's equity affiliate, Stonegate Capital Partners, "SCP" has a contractual agreement with the subject company to provide research services, investor relations support, and investor outreach. SCP receives a monthly retainer for these non-investment banking services.
- (e) Stonegate or its affiliates do not beneficially own 1% or more of any class of common equity securities of the subject company.
- (f) Stonegate does not make a market in the subject company.
- (g) The research analyst has not received any compensation from the subject company in the previous 12 months.
- (h) Stonegate, the research analyst, or associated person of Stonegate with the ability to influence the content of the research report knows or has reason to know of any material conflicts of interest at the time of publication or distribution of the research report.
- (i) No employee of Stonegate has a position as an officer or director of the subject company.

Ratings - Stonegate does not provide ratings for the covered companies.

Distribution of Ratings - Stonegate does not provide ratings for covered companies.

Price Chart - Stonegate does not have, nor has previously had, a rating for its covered companies.

Price Targets - Stonegate does not provide price targets for its covered companies. However, Stonegate does provide valuation analysis.

Regulation Analyst Certification:

I, Dave Storms, CFA, hereby certify that all views expressed in this report accurately reflect my personal views about the subject company or companies and its or their securities. I also certify that no part of my compensation was, is, or will be directly or indirectly related to the specific recommendations or views expressed in this report.

For Additional Information Contact:

Stonegate Capital Markets, Inc.
Dave Storms, CFA
Dave@stonegateinc.com
214-987-4121

Please note that this report was originally prepared and issued by Stonegate for distribution to their market professional and institutional investor customers. Recipients who are not market professional or institutional investor customers of Stonegate should seek the advice of their independent financial advisor prior to taking any investment decision based on this report or for any necessary explanation of its contents. The information contained herein is based on sources which we believe to be reliable but is not necessarily complete and its accuracy cannot be guaranteed. Because the objectives of individual clients may vary, this report is not to be construed as an offer or the solicitation of an offer to sell or buy the securities herein mentioned. This report is the independent work of Stonegate Capital Markets and is not to be construed as having been issued by, or in any way endorsed or guaranteed by, any issuing companies of the securities mentioned herein. The firm and/or its employees and/or its individual shareholders and/or members of their families and/or its managed funds may have positions or warrants in the securities mentioned and, before or after your receipt of this report, may make or recommend purchases and/or sales for their own accounts or for the accounts of other customers of the firm from time to time in the open market or otherwise. While we endeavor to update the information contained herein on a reasonable basis, there may be regulatory, compliance, or other reasons that prevent us from doing so. The opinions or information expressed are believed to be accurate as of the date of this report; no subsequent publication or distribution of this report shall mean or imply that any such opinions or information remains current at any time after the date of this report. All opinions are subject to change without notice, and we do not undertake to advise you of any such changes. Reproduction or redistribution of this report without the expressed written consent of Stonegate Capital Markets is prohibited. Additional information on any securities mentioned is available on request.